Skip to Main Content

Hello, everyone, and how are you are doing? STAT reporter Rebecca Robbins here, and I’m doing fine this morning, thanks to a steaming cup of stimulation. (No special flavor, though, I’m sorry to report.) Let’s get started on what you came here for: headlines from the world of pharma. And do send us a note if you spot anything interesting …

Novo Nordisk (NVO) scored a victory with its type 2 diabetes drug semaglutide in a late-stage trial, Reuters informs us. The drug combined with metformin successfully reduced glucose levels when tested head-to-head against a competitor from Eli Lilly (LLY).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!